Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516922 | 0.85 | PIK3CA (0.36) | HDAC1HDAC2 | |
| SCHEMBL23671531 | 0.85 | NOTUM (0.32) | NOTUMALDH1A1AKT1HPGD | |
| SCHEMBL23671543 | 0.76 | NOTUM (0.40) | NOTUMPDE4BAKT1 | |
| SCHEMBL23671574 | 0.73 | NPY2R (0.31) | — | |
| SCHEMBL28514637 | 0.71 | USP30 (0.35) | NOTUM | |
| SCHEMBL30898655 | 0.67 | NOTUM (0.63) | NOTUMHDAC1ALDH1A1AKT1 | |
| SCHEMBL2123320 | 0.67 | PDE4B (0.34) | PDE4BAKT1HPGD | |
| SCHEMBL23671532 | 0.66 | PIK3CA (0.42) | NOTUMALDH1A1AKT1 | |
| SCHEMBL17242122 | 0.65 | NOTUM (0.49) | NOTUMPDE4B | |
| SCHEMBL2123547 | 0.64 | PIK3CA (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | UCBBiopharma Srl (BE) | 2022-10-04 | — | — | US | disclosed |
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228547-A1 | Spirocyclic Indane Analogues as IL-17 Modulators | IL17A, IL18, IL23R | NOTUM 3996/4885PDE4B 2135/4885HDAC1 161/4885 |
| US-11458124-B2 | Spirocyclic indane analogues as IL-17 modulators | IL17A, IL18, IL23R | NOTUM 3996/4885PDE4B 2135/4885HDAC1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.